Share
12,001 Posts.
lightbulb Created with Sketch. 856
clock Created with Sketch.
16/12/19
09:29
Share
Originally posted by Wise_One:
↑
Lots of eyes on ANP this morning waiting for their Phase 2A final results treating DMD Sarepta Pharpa (US Listed) now worth US10B after popping 35% friday for FDA Approval on its DMD treatment drug. Noting however the FDA has grave concerns about it's safety profile, but approved it anyway "balancing risk / reward" for patients. If ANP's results this morning show no Safety Concerns it should fly given 30m mkt cap If, however, ANP can also demonstrate improvement in the disease (i.e. increase in patient strength) then it should go mental IMO Phase 2A trials have a safety primary endpoint only.
Expand
OT - Was just going to mention ANP but you beat me to it. Coming out of a halt today, pre-open looks good but that can change in a second depending on the announcement details. Definitely one to watch.